ESBL E coli and P. aeruginosa resistance to ceftolozane-tazobactam in a patient with a liver abscess. the search for an omnipotent antibiotic goes on!
Infectious Disorders - Drug Targets
© 2018 Bentham Science Publishers. Multi drug resistant (MDR) Pseudomonas aeruginosa and Extended-Spectrum-lactamase (ESBL) Enterobacteriaceae are becoming an increasing difficult clinical problem. Immediate resistance to some of the new antimicrobials such as ceftolozane/tazobactam is unusual and is due to a variety of mechanisms such as hyper-production of inactivating enzymes and gene mutation. In addition, previous antimicrobial administration is a well-recognized risk factor to develop resistance. We present a patient with a liver abscess where the organism was resistant to ceftolozane/tazobactam resulting in a poor clinical outcome.